Patrick McDermott
Endocrinology, Diabetes & Metabolism · West Hartford, CTNPI 1629188131
Payments from drug & device makers
Across 104 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$299
- Johnson & Johnson$160
- Amgen$153
- Sanofi-aventis U.S. LLC$124
- Lilly USA, LLC$112
- Abbott$108
- plus $783 from 17 others
What the payments were for
- Food & beverage$1,73199%
- Education$91%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $299 |
| Johnson & Johnson | 9 | $160 |
| Amgen | 10 | $153 |
| Sanofi-aventis U.S. LLC | 7 | $124 |
| Lilly USA, LLC | 8 | $112 |
| Abbott | 5 | $108 |
| AbbVie(2 entities) | 6 | $104 |
| AstraZeneca | 5 | $91 |
| Merck | 5 | $78 |
| Eisai Inc. | 3 | $58 |
| Amarin Pharma, Inc. | 3 | $53 |
| Boehringer Ingelheim | 3 | $52 |
| BD | 3 | $49 |
| Dexcom, Inc. | 2 | $45 |
| IBSA Pharma Inc. | 3 | $44 |
| Aytu Biopharma, Inc. | 2 | $39 |
| Radius Health, Inc. | 2 | $39 |
| Ascensia Diabetes Care US Inc. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Lifescan, Inc. | 1 | $19 |
| Valeritas, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Gilead | 1 | $16 |
How this compares
$1,740 in reported general payments places this provider in the 55th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 12 | $859 |
| SynthroidLevothyroxine Sodium | 11 | $853 |
| Levothyroxine Sodium | 61 | $669 |
| Atorvastatin Calcium | 60 | $560 |
| Metformin Hcl ErMetformin Hcl | 15 | $292 |
| Losartan Potassium | 16 | $187 |
| Sertraline Hcl | 17 | $183 |
| Amlodipine Besylate | 19 | $179 |
| Simvastatin | 13 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $104 | $85311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in West Hartford
- Elizabeth FasyWest Hartford$4K
- Ania JastreboffNew Haven$2.2M
- Ilja HulinskyBridgeport$1.6M
- Gerald ShulmanNew Haven$1M
- Karl InsognaNew Haven$903K
- Clemens BergwitzNew Haven$735K
- Egils BogdanovicsTorrington$608K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.